Organization (Academic)
DUKE UNIVERSITY
ClinicalTrials.gov lists DUKE UNIVERSITY as lead sponsor of 2,151 trials, counting the companies grouped under it. DUKE UNIVERSITY itself has 339 active development programs and 422 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 124 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 130 in 2026 and about 120 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (100 to 500), forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. 14 trials are registered to start in 2027 or later.
Logo Duke University, Shep, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers DUKE UNIVERSITY and 2 companies grouped under it: 2,151 lead-sponsored trials (2,057 its own, 94 in the grouped companies) and 4 legal-entity registrations (2 its own, 2 in the grouped companies).
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| RTI International | 83 | 1 |
| Duke Kunshan University | 11 | 1 |
Disease areas (867)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 149 |
| Substance-Related Disorders | 114 |
| Obesity | 111 |
| Diabetes Mellitus | 92 |
| Breast Neoplasms | 82 |
Showing 5 of 867 disease areas.
Trials by start year as sponsor or collaborator (37)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 14 trials are registered to start in 2027 or later, and not listed here.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 124 |
| 2025 | 108 |
| 2024 | 126 |
| 2023 | 144 |
| 2022 | 119 |
| 2021 | 152 |
| 2020 | 141 |
| 2019 | 127 |
| 2018 | 173 |
| 2017 | 164 |
Showing 10 of 37 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 140 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 1,610 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (339)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Tocilizumab | Arthritis, Juvenile | Phase 3 | 1 |
| Abatacept | Arthritis, Juvenile | Phase 3 | 1 |
| TNFi (Tumor Necrosis Factor inhibitor) medication | Arthritis, Juvenile | Phase 3 | 1 |
| (CP-6890,550) Tofacitinib | Arthritis, Juvenile | Phase 3 | 1 |
| Nicotine Patch | Substance-Related Disorders | Phase 3 | 11 |
Showing 5 of 339 active programs.
Approved assets (422)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Nicotine Patch | 20 |
| Bupropion | 11 |
| Ropivacaine | 8 |
| DEXAMETHASONE | 8 |
| Escitalopram | 7 |
Showing 5 of 422 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 34% hit target (n=869) | 38% on time (n=820) |
Journals published in (1,491)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 129 |
| JAMA | 107 |
| PloS one | 82 |
| Circulation | 81 |
| Lancet (London, England) | 61 |
Showing 5 of 1,491 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 2,386 | 487 | 2025-12-30 |
Financing and grant events (5,974)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-19 | NIH grant | 1,190,436 | Reporter |
| 2025-09-30 | NIH grant | 13,162 | Reporter |
| 2025-09-30 | NIH grant | 5,530,000 | Reporter |
| 2025-09-30 | NIH grant | 95,000 | Reporter |
| 2025-09-30 | NIH grant | 178,965 | Reporter |
Showing 5 of 5,974 events.
Organization relationships (460)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 209 |
| University of California System | Co sponsors trial with | 42 |
| University of North Carolina System | Co sponsors trial with | 26 |
| Johns Hopkins University | Co sponsors trial with | 21 |
| Roche (Switzerland) | Co sponsors trial with | 20 |
Showing 5 of 460 relationships.
Latest dated events (11,202)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2027-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2027-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 11,202 events.
Biomarker capability evidence (2,042)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AATF | Trial collaborator | Named in trial inclusion criteria |
| ABCD1 | Trial collaborator | Named in trial inclusion criteria |
| ABCD1 | Trial collaborator | Named in trial inclusion criteria |
| ABL1 | Trial sponsor | Named in trial inclusion criteria |
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 2,042 evidence rows.
Biomarkers this organization publishes on (4,504)
Shown in this order: most publications first.
Showing 5 of 4,504 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.